Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 4/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14629803 | 1.00 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL5907428 | 0.79 | FAAH (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2783090 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL25868 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2782415 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466673 | 0.73 | SMPD1 (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466582 | 0.73 | SMPD1 (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466941 | 0.73 | SMPD1 (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL466752 | 0.73 | SMPD1 (0.44) | FAAHCES1CES2MEN1CYP1A2 | |
| Phosphoric Acid SCHEMBL5312301 | 0.73 | FAAH (0.53) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528855-B2 | KRAS variant mRNA molecules | CureVac SE (DE) | 2026-01-20 | — | — | US | claimed |
| CN-119930462-A | RLRs receptor agonist based vaccine adjuvant lipid compounds, compositions comprising same and uses | 北京悦康科创医药科技股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119707862-A | RLRs receptor agonist based vaccine adjuvant lipid compounds, compositions comprising same and uses | 北京悦康科创医药科技股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119320387-A | Vaccine adjuvant lipid compound based on Toll-like receptor agonist and application thereof | 杭州天龙药业有限公司 | 2025-01-17 | — | — | CN | claimed |
| CN-117384055-B | Ionizable lipids for delivery of therapeutic agents and uses thereof | 仁景(苏州)生物科技有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118598769-A | Protonatable lipid compound, liposome, lipid nanoparticle and application thereof | 中国科学院广州生物医药与健康研究院 | 2024-09-06 | — | — | CN | claimed |
| CN-118388360-A | Long-acting spleen-targeted cationic lipid compound containing benzene ring structure, composition containing long-acting spleen-targeted cationic lipid compound and application of long-acting spleen-targeted cationic lipid compound | 北京悦康科创医药科技股份有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-117384055-A | Ionizable lipids for delivery of therapeutic agents and uses thereof | 仁景(苏州)生物科技有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117247359-A | Dendrimer-like lipid compound, liposome, lipid complex, lipid nanoparticle and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-12-19 | — | — | CN | claimed |
| US-20220340641-A1 | KRAS VARIANT MRNA MOLECULES | CUREVAC AG (DE) | 2022-10-27 | — | — | US | claimed |
| EP-1781593-B1 | CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS INC (CA) | 2011-12-14 | — | — | EP | claimed |
| CN-118265692-B | Carbon nucleus cationic lipid | 厦门赛诺邦格生物科技股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-118638021-A | Ionizable lipid compound, liposome, lipid nanoparticle and application thereof | 丹塔舟子医药技术(广州)有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118265692-A | Carbon nucleus cationic lipid | 厦门赛诺邦格生物科技股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-114805212-B | Lipid and lipid composition for delivery of therapeutic or prophylactic agents | 中国科学院基础医学与肿瘤研究所(筹) | 2024-06-18 | — | — | CN | disclosed |
| US-20240024516-A1 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | Translate Bio, Inc | 2024-01-25 | — | — | US | disclosed |
| CN-114746401-B | Ionizable lipids for nucleic acid delivery | 精密纳米系统无限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-112870163-A | Hybrid, composition containing the hybrid, preparation method and use thereof | 安杰瑞姆生物科学公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-2970940-B1 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | TRANSLATE BIO INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20160184458-A1 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528855-B2 | KRAS variant mRNA molecules | KRAS, NRAS, TP53 | FAAH 4074/4885CES1 4535/4885CES2 4884/4885 |
| US-20160184458-A1 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SYNCRIP, HNRNPAB, HNRNPA2B1 | FAAH 4052/4885CES1 2600/4885CES2 3005/4885 |
| US-20220340641-A1 | KRAS VARIANT MRNA MOLECULES | KRAS, NRAS, APC | FAAH 4372/4885CES1 4334/4885CES2 4882/4885 |
| US-20240024516-A1 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SYNCRIP, HNRNPAB, HNRNPA2B1 | FAAH 4052/4885CES1 2600/4885CES2 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.